###begin article-title 0
###xml 70 89 70 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Helicobacter pylori</italic>
###xml 70 89 <span type="species:ncbi:210">Helicobacter pylori</span>
Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells
###end article-title 0
###begin p 1
###xml 184 206 184 206 <email xmlns:xlink="http://www.w3.org/1999/xlink">avarro@liverpool.ac.uk</email>
Address for reprint requests and other correspondence: A. Varro, Physiological Laboratory, School of Biomedical Sciences, Univ. of Liverpool, Crown St., Liverpool L69 3BX, UK (e-mail: avarro@liverpool.ac.uk)
###end p 1
###begin p 2
This document may be redistributed and reused, subject to .
###end p 2
###begin p 3
###xml 21 40 21 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Helicobacter pylori</italic>
###xml 42 51 42 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 178 187 178 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 523 532 523 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 713 714 713 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 716 717 716 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 928 937 928 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 1010 1019 1010 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 1185 1194 1185 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 1612 1621 1612 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 21 40 <span type="species:ncbi:210">Helicobacter pylori</span>
###xml 42 51 <span type="species:ncbi:210">H. pylori</span>
###xml 178 187 <span type="species:ncbi:210">H. pylori</span>
###xml 523 532 <span type="species:ncbi:210">H. pylori</span>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
###xml 576 581 <span type="species:ncbi:9606">human</span>
###xml 928 937 <span type="species:ncbi:210">H. pylori</span>
###xml 1010 1019 <span type="species:ncbi:210">H. pylori</span>
###xml 1185 1194 <span type="species:ncbi:210">H. pylori</span>
###xml 1612 1621 <span type="species:ncbi:210">H. pylori</span>
The gastric pathogen Helicobacter pylori (H. pylori) is linked to peptic ulcer and gastric cancer, but the relevant pathophysiological mechanisms are unclear. We now report that H. pylori stimulates the expression of plasminogen activator inhibitor (PAI)-1, urokinase plasminogen activator (uPA), and its receptor (uPAR) in gastric epithelial cells and the consequences for epithelial cell proliferation. Real-time PCR of biopsies from gastric corpus, but not antrum, showed significantly increased PAI-1, uPA, and uPAR in H. pylori-positive patients. Transfection of primary human gastric epithelial cells with uPA, PAI-1, or uPAR promoters in luciferase reporter constructs revealed expression of all three in H+/K+ATPase- and vesicular monoamine transporter 2-expressing cells; uPA was also expressed in pepsinogen- and uPAR-containing trefoil peptide-1-expressing cells. In each case expression was increased in response to H. pylori and for uPA, but not PAI-1 or uPAR, required the virulence factor CagE. H. pylori also stimulated soluble and cell surface-bound uPA activity, and both were further increased by PAI-1 knockdown, consistent with PAI-1 inhibition of endogenous uPA. H. pylori stimulated epithelial cell proliferation, which was inhibited by uPA immunoneutralization and uPAR knockdown; exogenous uPA also stimulated proliferation that was further increased after PAI-1 knockdown. The proliferative effects of uPA were inhibited by immunoneutralization of the EGF receptor and of heparin-binding EGF (HB-EGF) by the mutant diphtheria toxin CRM197 and an EGF receptor tyrosine kinase inhibitor. H. pylori induction of uPA therefore leads to epithelial proliferation through activation of HB-EGF and is normally inhibited by concomitant induction of PAI-1; treatments directed at inhibition of uPA may slow the progression to gastric cancer.
###end p 3
###begin p 4
###xml 140 153 140 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 4
###begin p 5
###xml 0 26 0 26 <sc xmlns:xlink="http://www.w3.org/1999/xlink">infection with the gastric</sc>
###xml 37 56 37 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Helicobacter pylori</italic>
###xml 58 67 58 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r55">55</xref>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 887 888 887 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r56">56</xref>
###xml 37 56 <span type="species:ncbi:210">Helicobacter pylori</span>
###xml 58 67 <span type="species:ncbi:210">H. pylori</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
infection with the gastric bacterium Helicobacter pylori (H. pylori) is associated with inflammation of the gastric mucosa that, in some patients, progresses to tissue remodeling involving the development of a hyperproliferative condition and loss of some epithelial cell types, notably parietal cells (7, 8, 10, 11). These changes may lead eventually to gastric cancer (43, 44). Environmental and bacterial factors are both recognized to influence the progression of these changes with chronic infection. In addition, host factors that influence epithelial responses to infection have been identified including genetic background (18, 35), altered expression, and secretion of hormones, e.g., gastrin (33), growth factors such as heparin-binding epidermal growth factor (HB-EGF) (55), cytokines including IL-8 (12), and extracellular proteases such as matrix metalloproteinase (MMP)-7 (4, 13, 56). Although considerable progress has been made in recent years, the interactions between these systems are still poorly understood.
###end p 5
###begin p 6
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 797 799 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
In many different tissues, the responses to infection and injury include induction of members of the urokinase plasminogen activator (uPA) system (2). The key components of this system are uPA itself, which mediates the conversion of plasminogen to plasmin, its receptor (uPAR), which localizes uPA on the cell surface, and several plasminogen activator inhibitors (PAI-1, -2, and -3). Stimulation of uPA/plasmin is implicated in fibrinolysis, degradation of extracellular matrix, activation of other proteases including multiple MMPs, and modulation of cell-matrix interactions (2, 36). In addition to inhibition of uPA, both PAI-1 and PAI-2 are recognized to have uPA-independent actions. In the case of PAI-1, these are thought, at least in part, to be a consequence of binding to vitronectin (14). Moreover, although PAI-2 is a secreted protein, its signal sequence is relatively weak and there is a substantial pool of intracellular PAI-2 that is thought to play a role in inhibiting apoptosis (15); the biology of PAI-3 is not well understood. Until recently the role of this system in gastric physiology and pathophysiology was relatively unknown.
###end p 6
###begin p 7
###xml 104 113 104 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 360 369 360 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 476 485 476 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 104 113 <span type="species:ncbi:210">H. pylori</span>
###xml 360 369 <span type="species:ncbi:210">H. pylori</span>
###xml 476 485 <span type="species:ncbi:210">H. pylori</span>
###xml 524 529 <span type="species:ncbi:9606">human</span>
Recently, we reported increased expression of PAI-2 in the gastric epithelium in patients infected with H. pylori (54). Previous studies have contributed to the view that uPA, PAI-1, and uPAR are all associated with an adverse outcome in gastric cancer (21, 23, 27, 40, 46), as well as other tumors (1, 48). However, the roles of these proteins in response to H. pylori infection in the normal epithelium are unknown. In the present study, we therefore asked whether there is H. pylori stimulation of uPA, uPAR, or PAI-1 in human gastric epithelial cells; we report here that there is and that induction is linked to a proliferative response to infection.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Plasmids, drugs.
###end title 9
###begin p 10
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r52">52</xref>
###xml 137 142 <span type="species:ncbi:9606">Human</span>
###xml 401 406 <span type="species:ncbi:9606">human</span>
###xml 477 482 <span type="species:ncbi:9606">human</span>
PAI-1 antisense oligonucleotides (ASO) and control scrambled oligonucleotides (CSO) were obtained from Biognostik (Gottingham, Germany). Human recombinant uPA, EGF, tissue inhibitor of metalloproteinases (TIMP)-1, and TIMP-3, and GM6001 were obtained from Calbiochem (Nottingham, UK), and uPA activity kit was purchased from Chemicon (Chandlers Ford, UK). 1.94-kb, 4.5-kb, and 2.3-kb fragments of the human uPA, PAI-1 and uPAR promoters, respectively, were generated by PCR of human genomic DNA and cloned into the firefly luciferase reporter construct pXP2 using methods previously reported (52). Antibodies to uPA, PAI-1, and uPAR were obtained from American Diagnostica (Stamford, CT), antibody to the EGF receptor was purchased from Oncogene (Cambridge, MA), and antibodies to TGF-alpha, amphiregulin, and HB-EGF were obtained from R&D Systems (Abingdon, UK). uPAR and control siRNA was obtained from Ambion (Austin, TX). Other chemicals were obtained from Sigma (Poole, Dorset, UK).
###end p 10
###begin title 11
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients.
###end title 11
###begin p 12
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 163 172 161 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 595 596 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 706 715 702 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 123 126 <span type="species:ncbi:9606">men</span>
###xml 163 172 <span type="species:ncbi:210">H. pylori</span>
###xml 412 420 <span type="species:ncbi:9606">Patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
###xml 606 609 <span type="species:ncbi:9606">men</span>
###xml 706 715 <span type="species:ncbi:210">H. pylori</span>
###xml 932 940 <span type="species:ncbi:9606">patients</span>
Six endoscopic pinch biopsies of gastric corpus and antrum were obtained from patients referred with dyspepsia (n = 33, 18 men, mean age 54.2 +/- 1.7 yr) and with H. pylori infection confirmed by serology, antral urease test (Prontodry; Med. Inst. Solothurn, Switzerland), and antral and corpus histology; in all cases, histology indicated superficial gastritis but not gastric atrophy or intestinal metaplasia. Patients were excluded if there was a previous history of neoplastic disease, present history of peptic ulcer, or elevated plasma gastrin concentrations (>30 pM). Dyspeptic patients (n = 90, 46 men, mean age 53.9 +/- 1.3 yr) with normal fasting plasma gastrin concentrations (<30 pM), negative H. pylori status by serology, antral urease test, and antral and corpus histology were used as controls. The study was approved by the Ethics Committee of the Royal Liverpool and Broadgreen University Hospitals NHS Trust. All patients gave written, informed consent.
###end p 12
###begin title 13
Real-time PCR.
###end title 13
###begin p 14
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 168 194 <span type="species:ncbi:11866">avian myeloblastosis virus</span>
###xml 332 337 <span type="species:ncbi:9606">human</span>
RNA from human gastric biopsies was extracted in Trizol (Invitrogen, Paisley, UK) and DNase treated (Promega, Southampton, UK), and 5 mug were reverse transcribed with avian myeloblastosis virus reverse transcriptase (Promega) and random hexamers (Promega). Real-time PCR was carried out using TaqMan probe/primer sets specific for human uPA (forward primer 5'-ggaaaacctcatcctacacaagga; reverse primer 5'-cggatcttcagcaaggcaat; probe 5'-ctgacacgcttgctcaccacaacga), PAI-1 (forward primer 5'-ggctgacttcacgagtctttcag; reverse primer 5'-cgttcacctcgatcttcactttc; probe 5'-aagagcctctccacgtcgcgca), uPAR (forward primer 5'-cgaggttgtgtgtgggttagac; reverse primer 5'-ggcttcgggaataggtgaca; probe 5'-tgcaaccagggcaactctggcc), PAI-3 (forward primer 5'-tctgtgaccttatgctccacactaa; reverse primer 5'-gcatggtggctgttctttgtt; probe 5'-tctggcagagcctccgtttcctca), and an 18S rRNA control kit (Eurogentec, Southampton, UK). Reactions were performed in an Applied Biosystems (Warrington, UK) PrismTM7700 sequence detection system and quantified using a standard curve. uPA, uPAR, PAI-1, and PAI-3 mRNA abundances were determined relative to 18S in the same sample.
###end p 14
###begin title 15
Gastrin radioimmunoassay.
###end title 15
###begin p 16
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
Plasma samples were assayed for total amidated gastrin concentrations by radioimmunoassay using antibody L2 (which reacts with G17 and G34 but not progastrin or Gly-gastrins) as previously described (17).
###end p 16
###begin title 17
Immunohistochemistry.
###end title 17
###begin p 18
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r53">53</xref>
Formalin-fixed, paraffin-embedded tissue sections were processed for immunohistochemical detection of uPA, PAI-1, and uPAR after antigen recovery as previously described (53).
###end p 18
###begin title 19
###xml 9 14 <span type="species:ncbi:9606">human</span>
Cultured human gastric gland cells.
###end title 19
###begin p 20
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r56">56</xref>
###xml 221 222 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 228 229 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 9 14 <span type="species:ncbi:9606">human</span>
Adherent human gastric glands were prepared using the method previously described (56). Glands were cultured in DMEM/Hams F12 supplemented with 10% FBS and 1% antibiotic-antimycotic solution (Sigma) at 37degreesC in 5% CO2-95% O2.
###end p 20
###begin title 21
Knockdown of PAI-1 and uPA activity assays.
###end title 21
###begin p 22
###xml 213 215 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 299 308 298 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 391 393 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 299 308 <span type="species:ncbi:210">H. pylori</span>
Human gastric glands were cultured as monolayers and treated with 2 muM PAI-1 ASO sodium salt or the corresponding negative control oligonucleotide (CSO) sodium salt (Biognostik) for 72 h as previously described (37). Knockdown of PAI-1 was verified by immunocytochemistry. Cells were infected with H. pylori strain 60190 [American Type Culture Center (ATCC)] for 16 h as described earlier (49). uPA activity assay was performed from both media and cell extracts according the manufacturer's instruction and absorption measured at 340 nm.
###end p 22
###begin title 23
###xml 58 63 <span type="species:ncbi:9606">human</span>
Transient transfection and bacterial infection of primary human gland cultures.
###end title 23
###begin p 24
###xml 178 185 177 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
###xml 319 321 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 349 358 348 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 484 485 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 487 489 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 8 13 <span type="species:ncbi:9606">human</span>
###xml 212 216 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 349 358 <span type="species:ncbi:210">H. pylori</span>
Primary human gastric glands cultured for 48 h on 12-well plates were transfected with 2 mug firefly luciferase reporter construct per well together with a constitutively active Renilla luciferase reporter, phRL-SV40 (5 ng per well, Promega), using CombiMag (Oz Biosciences, Marseille, France) as previously described (49). Cells were infected with H. pylori strain 60190 (ATCC) and its isogenic mutants at a multiplicity of infection (MOI) of 1:150 for 16 h as described previously (3, 54). Luciferase activity was measured by dual luciferase assay (Promega) in a Lumat LB9507 luminometer (Berthold, Redbourne, UK). Results are presented as fold increase over unstimulated control, so a value of 1.0 signifies no change in luciferase activity.
###end p 24
###begin title 25
###xml 63 68 <span type="species:ncbi:9606">human</span>
Cellular targeting of the members of the uPA system in primary human adherent glands.
###end title 25
###begin p 26
###xml 372 373 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 375 376 375 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 1183 1185 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 101 106 <span type="species:ncbi:9606">human</span>
###xml 153 157 <span type="species:ncbi:9925">goat</span>
###xml 265 271 <span type="species:ncbi:9986">rabbit</span>
###xml 359 365 <span type="species:ncbi:9986">rabbit</span>
###xml 397 403 <span type="species:ncbi:9986">rabbit</span>
###xml 449 454 <span type="species:ncbi:10090">mouse</span>
###xml 515 520 <span type="species:ncbi:10090">mouse</span>
###xml 1076 1084 <span type="species:ncbi:9606">patients</span>
To study cellular targeting of uPA, uPAR, and PAI-1-luciferase (luc) expression, transfected primary human gastric glands were double immunostained with goat anti-luciferase antibody (Rockland Immunochemicals, Gilbertsville, PA) together with one of the following: rabbit anti-pepsinogen (gift f;rom Mike Samloff, Center for Ulcer Research, Los Angeles, CA), rabbit anti-H+/K+ATPase (Calbiochem), rabbit anti-vesicular monoamine transporter 2 (22), mouse anti-trefoil factor-1 (TFF-1; Dako, Glostrup, Denmark), and mouse anti-TFF-2 (NovoCastra, Newcastle-upon-Tyne, UK) antibodies with appropriate FITC or Texas red-conjugated secondary antibodies (Jackson Immunoresearch, Soham, UK), using Vectashield mounting medium with DAPI (Vector Laboratories, Peterborough, UK) to counterstain nuclei. Slides were examined using a Zeiss Axioplan-2 microscope (Zeiss Vision, Welwyn Garden City, UK) and images captured using a JVC-3 charge-coupled device camera and KS300 software combined with a deconvolution software (Imaging Associates, Bicester, UK). Ten fields from each of three patients were counted; results are expressed as a percentage of total cell number as reported earlier (49, 54).
###end p 26
###begin title 27
BrdU labeling.
###end title 27
###begin p 28
###xml 28 37 28 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 256 265 256 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 561 563 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 1007 1009 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 28 37 <span type="species:ncbi:210">H. pylori</span>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 256 265 <span type="species:ncbi:210">H. pylori</span>
Primary gastric glands from H. pylori-negative and -positive patients were plated on cover slips in 12-well plates and cultured for 48 h. Glands were then serum starved for 24 h before addition of bromodeoxyuridine (BrdU) (3 ng/ml) with uPA (500 ng/ml) or H. pylori (MOI 1:150) and further incubated for 24 h at 37degreesC. Control scrambled and PAI-1 antisense oligonucleotides were present for 72 h as described above. Control or siRNA to uPAR were transfected using SilenceMag (Oz Biosciences) as previously described and cells incubated for a further 48 h (37). BrdU was detected with FITC-conjugated fast immune anti-BrdU/DNase (Becton Dickinson, Oxford, UK) using Vectashield mounting medium with DAPI (Vector Laboratories) to counterstain nuclei. Glands were counterstained with vimentin (RDI, Flanders, NJ) and cells with colocalized BrdU and vimentin-positive staining (myofibroblasts) were excluded. BrdU-positive cells were expressed as a percentage of total cell number as previously described (37).
###end p 28
###begin title 29
Statistics.
###end title 29
###begin p 30
###xml 84 85 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 145 146 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Results are presented as means +/- SE; comparisons were made using ANOVA or Student t-tests where appropriate and were considered significant at P < 0.05.
###end p 30
###begin title 31
RESULTS
###end title 31
###begin title 32
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 74 83 <span type="species:ncbi:210">H. pylori</span>
Increased expression of uPA, uPAR, and PAI-1 in human gastric corpus with H. pylori infection.
###end title 32
###begin p 33
###xml 162 171 162 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 179 180 179 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 173 180 173 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 443 452 443 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 483 484 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 477 484 477 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 547 556 547 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 875 884 871 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 1031 1040 1027 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 1052 1058 1048 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 1060 1061 1056 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1066 1067 1062 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 115 120 <span type="species:ncbi:9606">human</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 162 171 <span type="species:ncbi:210">H. pylori</span>
###xml 443 452 <span type="species:ncbi:210">H. pylori</span>
###xml 524 532 <span type="species:ncbi:9606">patients</span>
###xml 547 556 <span type="species:ncbi:210">H. pylori</span>
###xml 875 884 <span type="species:ncbi:210">H. pylori</span>
###xml 1031 1040 <span type="species:ncbi:210">H. pylori</span>
The results from real-time PCR indicated that uPA, uPAR, and PAI-1 mRNA abundances were significantly increased in human gastric corpus in patients infected with H. pylori (Fig. 1A). These changes appear to be specific in that there was no significant difference in the abundance of PAI-3 mRNA in gastric corpus, and neither was there a significant difference in the abundance of uPA, uPAR, or PAI-1 in the antrum of individuals infected with H. pylori compared with controls (Fig. 1B). Plasma gastrin concentrations in the patients infected with H. pylori used in this study (21.5 +/- 1.6 pM) were within the normal range and were not significantly different from the control group (20.7 +/- 1.7 pM), so the differences are not attributable to raised plasma gastrin. Immunohistochemical studies indicated that there was increased PAI-1, uPAR, and uPA in epithelial cells in H. pylori-positive subjects, including parietal cells. However, in the case of uPA and uPAR, there was also abundant expression in subepithelial cells with H. pylori infection (Fig. 1, C and D).
###end p 33
###begin title 34
###xml 0 9 <span type="species:ncbi:210">H. pylori</span>
###xml 102 107 <span type="species:ncbi:9606">human</span>
H. pylori increases uPA-, uPAR- and PAI-1-promoter/luciferase-reporter expression in primary cultured human gastric glands by distinct mechanisms.
###end title 34
###begin p 35
###xml 21 30 21 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 412 413 412 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 415 416 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 609 615 609 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 617 618 617 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 619 620 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 848 849 848 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 842 849 842 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 926 927 926 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 920 927 920 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 1342 1348 1342 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 1350 1351 1350 1351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1352 1353 1352 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1720 1729 1720 1729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 1731 1737 1731 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 1739 1740 1739 1740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1741 1742 1741 1742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 21 30 <span type="species:ncbi:210">H. pylori</span>
###xml 92 97 <span type="species:ncbi:9606">human</span>
###xml 1720 1729 <span type="species:ncbi:210">H. pylori</span>
To determine whether H. pylori directly stimulated transcription of PAI-1, uPAR, and uPA in human gastric epithelial cells, we transfected cultured gastric glands with constructs of PAI-1, uPAR, and uPA promoters coupled to a luciferase reporter (i.e., PAI-1-luc, uPAR-luc, and uPA-luc). In untransfected cells, there was expression of wild-type uPA, uPAR, and PAI-1 in subsets of parietal cells (identified by H+/K+ATPase staining), chief cells (identified by pepsinogen staining), enhanced chemiluminescence (ECL) cells (identified by chromogranin staining), and mucus cells (identified by TFF-1 staining) (Fig. 2, A-E). Generally, around 25-30% of parietal, chief, or ECL cells expressed uPA, uPAR, or PAI-1; however, PAI-1 was expressed in a relatively high proportion of ECL cells, and uPA was expressed in less than 10% of chief cells (Fig. 2E). uPA, uPAR, or PAI-1 were expressed in less than 15% of mucus cells (Fig. 2E). In cells transfected with luciferase promoter-reporter vectors, dual labeling immunofluorescence using antibodies to luciferase and to markers of parietal and ECL cells indicated that expression of the constructs was predominantly targeted to these cells. In addition, however, there was some expression of uPA-luc in chief cells and relatively low expression of uPAR-luc in either chief or surface mucus cells (Fig. 3, A-D). However, the promoter sequences used in these vectors were not able to direct detectable expression of PAI-1-luc in chief cells or of PAI-1 or uPA-luc in mucus cells indicated by TFF-1 immunoreactivity, or of PAI-1-, uPA- or uPAR-luc in mucus neck cells indicated by TFF-2 expression. Importantly, expression of each luciferase vector was increased in response to H. pylori (Fig. 4, A-C).
###end p 35
###begin p 36
###xml 59 68 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagA</italic>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagE</italic>
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vacA</italic>
###xml 278 287 278 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagE</italic>
###xml 394 403 394 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 430 436 430 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 438 439 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 440 441 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 460 469 460 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 59 68 <span type="species:ncbi:210">H. pylori</span>
###xml 278 287 <span type="species:ncbi:210">H. pylori</span>
###xml 394 403 <span type="species:ncbi:210">H. pylori</span>
###xml 460 469 <span type="species:ncbi:210">H. pylori</span>
To determine whether recognized major virulence factors of H. pylori were responsible for stimulation of uPA, uPAR, and PAI-1, isogenic mutants were studied in which the virulence genes cagA, cagE, and vacA were disrupted. Disruption of these virulence factors had no effect on H. pylori-stimulated PAI-1 or uPAR expression, but disruption of cagE virtually abolished the stimulatory effect of H. pylori on the uPA-luc construct (Fig. 4, A-C), indicating that H. pylori acts through separate mechanisms to stimulate PAI-1, uPA, and uPAR.
###end p 36
###begin title 37
###xml 0 9 <span type="species:ncbi:210">H. pylori</span>
###xml 45 50 <span type="species:ncbi:9606">human</span>
H. pylori increases uPA activity in cultured human gastric glands, which is enhanced by PAI-1 knockdown.
###end title 37
###begin p 38
###xml 57 66 57 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 170 179 170 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 240 246 240 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 557 563 553 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 565 566 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 571 572 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 57 66 <span type="species:ncbi:210">H. pylori</span>
###xml 170 179 <span type="species:ncbi:210">H. pylori</span>
Since both uPA and its inhibitor PAI-1 were increased by H. pylori, we asked whether there were changes in uPA enzyme activity. Infection of cultured gastric glands with H. pylori increased both cell surface-bound and soluble uPA activity (Fig. 5). We then examined the consequences of PAI-1 knockdown. Immunohistochemistry confirmed that PAI-1 antisense oligonucleotide treatment significantly decreased the total number of cells in cultured gastric glands expressing endogenous PAI-1 (CSO, 10.0 +/- 0.3% vs. ASO, 3.8 +/- 0.2%). Moreover, PAI-1 knockdown (Fig. 5, A and B) increased both cell surface-bound and soluble uPA activity although the increase was more marked for the latter than the former.
###end p 38
###begin title 39
###xml 0 9 <span type="species:ncbi:210">H. pylori</span>
H. pylori acts via uPA to increase epithelial cell proliferation, and PAI-1 knockdown enhances this response.
###end title 39
###begin p 40
###xml 52 61 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r55">55</xref>
###xml 234 243 234 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 342 343 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 336 343 336 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 537 543 537 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6</xref>
###xml 545 546 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 551 552 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 52 61 <span type="species:ncbi:210">H. pylori</span>
###xml 197 202 <span type="species:ncbi:9606">human</span>
###xml 234 243 <span type="species:ncbi:210">H. pylori</span>
Previous work has linked proliferative responses to H. pylori with activation of the EGF receptor, including stimulation of the ligand HB-EGF and its liberation by proteolysis (29, 55). In primary human gastric glands, we showed that H. pylori increased BrdU incorporation and that the response was further enhanced by PAI-1 knockdown (Fig. 6A). Consistent with the idea that PAI-1 inhibited uPA in this system, we then showed that uPA itself increased BrdU incorporation, and the response was again further enhanced by PAI-1 knockdown (Fig. 6, B and C).
###end p 40
###begin p 41
###xml 93 102 93 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 159 166 159 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>A</italic></xref>
###xml 292 301 292 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 331 332 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 325 332 325 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>A</italic></xref>
###xml 763 764 755 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 757 764 749 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>B</italic></xref>
###xml 93 102 <span type="species:ncbi:210">H. pylori</span>
###xml 292 301 <span type="species:ncbi:210">H. pylori</span>
Treatment of cells with a neutralizing antibody to uPA inhibited the proliferative effect of H. pylori, suggesting a role for endogenous uPA in this response (Fig. 7A). A role for uPAR in the response was indicated by the observation that knockdown of uPAR with siRNA significantly inhibited H. pylori-induced proliferation (Fig. 7A). Immunohistochemistry confirmed that siRNA treatment significantly decreased the number of uPAR-expressing cells in cultured gastric glands (control, 9.1 +/- 0.5% of positive cells; uPAR knockdown, 3.0 +/- 0.4%), whereas PAI-1 expression was not altered (8.4 +/- 0.5% vs. 8.8 +/- 0.4%). Consistent with these observations, the increased BrdU incorporation in response to exogenous uPA was also decreased by uPAR knockdown (Fig. 7B). The specificity of the latter effect is indicated by the fact that there was no decrease in BrdU incorporation after uPAR knockdown in response to an exogenous EGF receptor (EGF-R) ligand (EGF, 50 ng/ml) compared with control (EGF alone, 2.14 +/- 0.05-fold increase in BrdU incorporation over control; EGF and uPAR knockdown, 2.36 +/- 0.03-fold).
###end p 41
###begin title 42
uPA increases epithelial cell proliferation via metalloproteinase release of HB-EGF.
###end title 42
###begin p 43
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 324 331 324 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f8" ref-type="fig">Fig. 8<italic>A</italic></xref>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 425 432 425 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f8" ref-type="fig">Fig. 8<italic>B</italic></xref>
###xml 593 594 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 587 594 587 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f8" ref-type="fig">Fig. 8<italic>B</italic></xref>
###xml 1046 1048 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 1316 1317 1298 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1381 1382 1361 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Since there was increased BrdU incorporation in response to exogenous EGF, we asked whether the proliferative response to uPA was linked to activation of the EGF pathway. Neutralizing antibody against EGF-R significantly reduced BrdU incorporation induced by uPA, and so too did the EGF-R tyrosine kinase inhibitor, AG1478 (Fig. 8A). Moreover, neutralizing antibody to HB-EGF inhibited BrdU incorporation in response to uPA (Fig. 8B), and, in agreement with the idea that HB-EGF mediated responses to uPA, the mutant diphtheria toxin CRM197 also reduced uPA-mediated BrdU incorporation (Fig. 8B). Interestingly, however, responses to uPA were not influenced by neutralization of other EGF-R ligands such as amphiregulin and TGF-alpha that are known to be expressed in gastric mucosa (uPA, 1.90 +/- 0.12-fold increase over control; uPA and amphiregulin immunoneutralization, 1.74 +/- 0.15-fold over control; uPA and TGF-alpha immunoneutralization, 2.10 +/- 0.15-fold over control). Since it is known that HB-EGF is released by metalloproteinases (47), we examined the effect of a broad spectrum inhibitor, GM6001, and two tissue inhibitors of MMPs (TIMP-1 and TIMP-3) on proliferative response to uPA. At a concentration of 100 nM, TIMP-1 inhibited BrdU incorporation by 21 +/- 5% and TIMP-3 inhibited by 69 +/- 10% (P < 0.05), whereas GM6001 inhibited uPA responses by 70 +/- 12% (P < 0.05).
###end p 43
###begin title 44
DISCUSSION
###end title 44
###begin p 45
###xml 27 36 27 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 409 418 409 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 565 574 565 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 625 634 625 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 901 910 901 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 994 1003 994 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 27 36 <span type="species:ncbi:210">H. pylori</span>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 409 418 <span type="species:ncbi:210">H. pylori</span>
###xml 565 574 <span type="species:ncbi:210">H. pylori</span>
###xml 625 634 <span type="species:ncbi:210">H. pylori</span>
###xml 901 910 <span type="species:ncbi:210">H. pylori</span>
###xml 994 1003 <span type="species:ncbi:210">H. pylori</span>
The present data show that H. pylori infection of the human gastric corpus is associated with increased expression of uPA, its receptor uPAR, and its inhibitor PAI-1. It seems probable that separate mechanisms are associated with increased expression of uPA, uPAR, and PAI-1. Thus within the epithelium, both parietal and ECL cells have the capacity to increase uPA, uPAR, and PAI-1 expression in response to H. pylori, whereas chief cells can also express uPA, and mucus cells may express uPAR. Moreover, the CagE virulence factor is required for uPA responses to H. pylori but not PAI-1 or uPAR. A role for uPA and uPAR in H. pylori-stimulated cell proliferation was identified through mechanisms that required HB-EGF and EGF-R activation and were at least partly held in check by PAI-1. The data implicate activation of uPA in the preneoplastic hyperproliferative condition that is associated with H. pylori infection. Control of uPA activity may therefore present a new target in arresting H. pylori-stimulated progression to cancer.
###end p 45
###begin p 46
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1244 1253 1244 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 1244 1253 <span type="species:ncbi:210">H. pylori</span>
Previous work has established that uPA, uPAR, and PAI-1 are increased in gastric cancer and in chronic atrophic gastritis (6, 19, 21, 23, 27, 28, 40, 46); moreover, increased expression in cancer is associated with an adverse outcome. There is expression of uPA, uPAR, and PAI-1 in both stromal and tumor cells, and it is generally thought that the expression of these proteins is associated with progression of the disease through increased cell invasion, metastasis, and angiogenesis. In the case of uPA, binding to uPAR generates a focal point of proteolytic activity that facilitates cell invasion (1). In addition to inhibition of uPA through accelerated internalization of the uPA/uPAR complex, PAI-1 also exhibits uPA-independent actions. Specifically, by binding vitronectin it increases cell dissociation from extracellular matrix and accelerates invasion (14). It has been suggested that the latter effects account for the association of increased PAI-1 in gastric and other cancers with adverse outcomes, which is sometimes referred to as "paradoxical" given that uPA is also associated with disease progression. In spite of the work on uPA and PAI-1 in gastric cancer, little attention has been given to how this system responds to H. pylori infection and how it might be implicated in the tissue remodeling that characterizes the preneoplastic condition.
###end p 46
###begin p 47
###xml 89 98 89 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 128 130 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 330 332 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 390 399 386 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 589 598 585 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 689 698 685 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 772 774 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 848 857 844 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 906 908 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 910 912 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 914 916 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 1725 1727 1721 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 1768 1777 1764 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 2550 2559 2546 2555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 89 98 <span type="species:ncbi:210">H. pylori</span>
###xml 390 399 <span type="species:ncbi:210">H. pylori</span>
###xml 589 598 <span type="species:ncbi:210">H. pylori</span>
###xml 689 698 <span type="species:ncbi:210">H. pylori</span>
###xml 848 857 <span type="species:ncbi:210">H. pylori</span>
###xml 1768 1777 <span type="species:ncbi:210">H. pylori</span>
###xml 1787 1795 <span type="species:ncbi:9606">patients</span>
###xml 2550 2559 <span type="species:ncbi:210">H. pylori</span>
We previously showed that PAI-2 was increased in gastric epithelial cells in response to H. pylori via activation of NF-kappaB (54). A pool of PAI-2 is retained within cells and is associated with inhibition of apoptosis, whereas some is secreted and has been shown to be involved in inhibition of invasion of a cancer cell line (54). The present data now make it clear that infection with H. pylori also induces the main members of the system, uPA, uPAR, and PAI-1 in primary, untransformed, gastric epithelial cells; there was no evidence that a third inhibitor, PAI-3, was changed with H. pylori infection, and we did not study this further. Previous work using microarrays to identify H. pylori-regulated genes demonstrated increased uPA in gastric cancer cell lines (32), and there has been work using gastric cancer cell lines that indicates H. pylori stimulation of uPA, uPAR, and PAI-1 expression (24, 30, 31). However, given the nature of cancer cell lines, it remained uncertain how these observations related to expression of members of the uPA system in primary gastric epithelial cells. Our data show that with infection there is the capacity to increase uPA, uPAR, and PAI-1 expression in two cell types associated with the gastric corpus, namely the acid-secreting parietal cell and the histamine-releasing enterochromaffin-like cell; the restriction of both cell types to the gastric corpus is consistent with the observation that there was no difference in expression of uPA, uPAR, and PAI-1 in the antral region of the stomach (where these cell types are absent). In contrast, PAI-2 is prominently expressed in mucin- and pepsinogen-expressing cells and is only occasionally found in parietal or ECL cells (54); it is also increased in the antrum in H. pylori-positive patients (S. Kenny and A. Varro, unpublished observations). Interestingly, only subsets of the major differentiated gastric epithelial cell types expressed uPA, uPAR, or PAI-1; the basis of this requires further work because the different subsets might, for example, vary in terms of age. It is clear that promoters of the length we used in the luciferase reporter vectors do not precisely mimic the patterns of expression of the wild-type gene, indicating that information outside these sequences is required for faithful cell-restricted expression. Even so, at a qualitative level the general patterns of expression of the wild-type proteins and the promoter-reporter vectors were similar. Importantly, the increased abundance of uPA transcripts in response to H. pylori was associated with increased enzyme activity in normal gastric epithelial cells that was enhanced still further by blocking PAI-1 expression compatible with a dynamic equilibrium between enzyme and its inhibitor, and with the idea that the changes in transcript abundance were functionally relevant.
###end p 47
###begin p 48
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 238 247 238 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 308 317 308 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 451 460 451 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 601 605 601 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagE</italic>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagE</italic>
###xml 684 693 684 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 932 936 928 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagA</italic>
###xml 1011 1015 1007 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagE</italic>
###xml 1172 1174 1160 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1176 1178 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 1180 1182 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 1184 1186 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 1249 1258 1237 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 1339 1341 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 0 9 <span type="species:ncbi:210">H. pylori</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 238 247 <span type="species:ncbi:210">H. pylori</span>
###xml 308 317 <span type="species:ncbi:210">H. pylori</span>
###xml 451 460 <span type="species:ncbi:210">H. pylori</span>
###xml 684 693 <span type="species:ncbi:210">H. pylori</span>
###xml 1249 1258 <span type="species:ncbi:210">H. pylori</span>
H. pylori increases plasma gastrin concentrations, and parietal and ECL cells express the CCK-2 receptor at which gastrin acts (16, 33). However, increased abundance of uPA, uPAR, and PAI-1 transcripts was found in patients infected with H. pylori with plasma gastrin concentrations in the normal range, and H. pylori stimulation of promoter-reporter constructs occurred in epithelial cells in vitro (in the absence of gastrin) so that the effects of H. pylori are not secondary to increased gastrin. Although stimulation of uPAR and PAI-1 was independent of the pathogenicity island, we found that a cagE isogenic mutant was defective in uPA induction. Disruption of cagE means that H. pylori cannot make a functional type IV secretory apparatus. This has two effects: first, it blocks Nod1-NF-kappaB signaling, and second, it blocks delivery of CagA into epithelial cells and the signaling consequent on this. Since disruption of cagA had no effect on uPA induction, it is likely that the deficit seen in the cagE mutant is due to lack of stimulation of Nod1-NF-kappaB. This is compatible with the already described role of NF-kappaB in regulation of uPA transcription (20, 28, 38, 42). It is worth noting that, in MKN-45 and KATO III cell lines, H. pylori stimulation of uPA expression was reported to be abolished by mutation of CagA (24); differences between cancer cell lines and primary, untransformed, cells used in the present study may well account for this difference.
###end p 48
###begin p 49
###xml 14 23 14 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 93 102 93 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 190 199 190 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r55">55</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1309 1311 1297 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r50">50</xref>
###xml 1331 1333 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r51">51</xref>
###xml 1335 1337 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r57">57</xref>
###xml 1356 1358 1344 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 1523 1525 1511 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 1527 1529 1515 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 1880 1889 1868 1877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 2183 2185 2171 2173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 14 23 <span type="species:ncbi:210">H. pylori</span>
###xml 93 102 <span type="species:ncbi:210">H. pylori</span>
###xml 190 199 <span type="species:ncbi:210">H. pylori</span>
###xml 390 395 <span type="species:ncbi:9606">human</span>
###xml 1880 1889 <span type="species:ncbi:210">H. pylori</span>
The data link H. pylori induction of uPA to one of the key characteristics of preneoplastic, H. pylori-infected epithelium, namely increased cell proliferation. Previous work has shown that H. pylori stimulates proliferation and that this includes transactivation of the EGF receptor and stimulation of HB-EGF cleavage (29, 45, 55). We demonstrate that the proliferative response of normal human gastric epithelial cells to uPA is mediated by EGF-R. It is possible that there are interactions between ligand-bound uPAR and EGF-R that result in proliferation (25). However, the cells expressing uPAR in gastric glands (mainly parietal and ECL cells) are distinct from the proliferating cells, and, instead, the data suggest that uPA stimulates proliferation via the release of an EGF-R ligand, HB-EGF. This system is therefore distinct from prostatic DU-145 cells in which uPA-stimulated invasion is mediated by HB-EGF in an autocrine mechanism (9). Other ligands of EGF-R produced in the gastric epithelium include amphiregulin and TGF-alpha; however, in contrast to HB-EGF, immunoneutralization of amphiregulin and TGF-alpha did not inhibit the proliferative responses to uPA. It is known that HB-EGF is cleaved from its cell-bound precursor via proteases that include TNF-alpha-converting enzyme (ADAM-17) (50), MMP-3 and MMP-7 (51, 57), and matrilysin (41). There is also a considerable body of evidence indicating that in different systems there are cascades of proteolytic activation involving uPA, plasmin, and MMPs (34, 39). The data show GM6001, TIMP-1, and TIMP-3 inhibit the action of uPA, consistent with a role for metalloproteinases downstream of uPA although the precise sequence of events by which uPA activates HB-EGF remains to be determined. In this context, it is worth noting, however, that, although uPA activates MMPs and MMPs are known to be increased with H. pylori infection, the localization of MMPs in the gastrointestinal mucosa is for the most part subepithelial. Within the normal gastric epithelium, MMP-7 is the predominant representative of this group, and we have already shown that this does not stimulate proliferation in cultured gastric glands (37).
###end p 49
###begin p 50
###xml 150 159 150 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 396 406 396 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori,</italic>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 150 159 <span type="species:ncbi:210">H. pylori</span>
###xml 396 405 <span type="species:ncbi:210">H. pylori</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
The well-established association of uPA with pericellular proteolysis in tissue damage and repair raises the prospect that induction of the system in H. pylori infection is part of a host response mechanism relevant to the tissue remodeling characteristic of this infection. Previous work has established a variety of different ways that bacteria interact with the uPA system (5). In the case of H. pylori, two plasminogen-binding proteins have been identified that are proposed to coat the organism, and, with the subsequent activation of bound plasminogen to plasmin, these proteins are thought to increase virulence (26). The present data suggest a further role for this system in stimulation of cell proliferation. With prolonged infection, we suggest that the increased proliferation favors the acquisition of mutations leading to cancer. The present data therefore raise the possibility that inhibition of uPA might be therapeutically useful in those patients at risk of progression from gastric atrophy to cancer.
###end p 50
###begin title 51
GRANTS
###end title 51
###begin p 52
This work was supported by Medical Research Council, The Wellcome Trust, and Wolfson Foundation.
###end p 52
###begin p 53
###xml 51 60 51 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 51 60 <span type="species:ncbi:210">H. pylori</span>
We are grateful to Mrs. Debbie Sales for culturing H. pylori, Mr. Andy Dodson for technical help with the immunohistochemistry, and Dr. Fiona Campbell for help with the interpretation of uPA, uPAR, and PAI-1 staining.
###end p 53
###begin title 54
REFERENCES
###end title 54
###begin p 55
###xml 174 193 174 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Helicobacter pylori</italic>
###xml 195 204 195 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 207 208 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 333 342 333 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 344 345 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 347 348 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 399 400 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 411 412 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 429 430 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 523 532 523 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 567 568 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 579 580 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 745 754 745 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 756 757 756 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 174 193 <span type="species:ncbi:210">Helicobacter pylori</span>
###xml 195 204 <span type="species:ncbi:210">H. pylori</span>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
###xml 333 342 <span type="species:ncbi:210">H. pylori</span>
###xml 509 517 <span type="species:ncbi:9606">patients</span>
###xml 523 532 <span type="species:ncbi:210">H. pylori</span>
###xml 699 706 <span type="species:ncbi:9606">patient</span>
###xml 723 730 <span type="species:ncbi:9606">patient</span>
###xml 745 754 <span type="species:ncbi:210">H. pylori</span>
Increased gastric urokinase plasminogen activator (uPA), uPA receptor (uPAR) and plasminogen activator inhibitor (PAI)-1, but not PAI-3, expression in patients infected with Helicobacter pylori (H. pylori). A: real-time PCR normalized to 18S shows elevated uPA, uPAR, and PAI-1 mRNA expression in the gastric corpus in patients with H. pylori (H. p.) infection compared with uninfected individuals (n = 13-14, *P < 0.05, ANOVA). B: there was no increase in the antrum in uPA, uPAR, or PAI-1 mRNA abundance in patients with H. pylori infection compared with controls (n = 11-20). C: representative examples of low uPA, uPAR, and PAI-1 staining of serial sections of gastric corpus from an uninfected patient compared with a patient infected with H. pylori (D); control section: first antibody omitted. Black arrows, staining of epithelial cells; yellow arrows, stromal cells.
###end p 55
###begin p 56
###xml 69 70 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 148 154 148 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 337 343 337 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 409 413 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 493 499 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 515 520 515 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 523 524 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 554 558 554 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 566 567 566 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 569 570 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 613 619 613 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 635 640 635 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 643 644 643 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 665 666 665 666 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 781 782 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 174 180 <span type="species:ncbi:9793">donkey</span>
###xml 186 192 <span type="species:ncbi:9986">rabbit</span>
###xml 218 224 <span type="species:ncbi:9793">donkey</span>
###xml 230 235 <span type="species:ncbi:10090">mouse</span>
Expression of uPA, uPAR, and PAI-1 in human cultured gastric glands. A: controls where primary antibody was omitted (left, DAPI staining of nuclei; middle, Texas red-labeled donkey anti-rabbit IgG; right, FITC-labeled donkey anti-mouse IgG). B: example of expression of uPAR (green, left) in a pepsinogen-positive cell (chief cell, red, middle; merged image, right). C: example of expression of PAI-1 (green, left) in a chromogranin-positive cell, [enhanced chemiluminescence (ECL) cell, red, middle; merged image, right]. D: expression of PAI-1 (green, left) in a H+/K+ ATPase-positive cell (parietal cell, red, middle; merged image, right). E: percentage (%) of H+/K+ATPase-, pepsinogen-, chromogranin-, and trefoil peptide (TFF)-1-positive cells expressing PAI-1, uPAR, or uPA (n = 3). Note that <3.0% of TFF-2-expressing cells expressed uPA, uPAR, or PAI-1.
###end p 56
###begin p 57
###xml 290 291 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 325 329 325 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 340 341 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 406 411 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 414 415 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 530 536 530 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 560 561 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 593 597 593 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 647 653 647 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 669 674 669 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 677 678 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 757 758 757 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 760 761 760 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 792 793 792 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 258 263 <span type="species:ncbi:9606">human</span>
uPA, uPAR, and PAI-1 promoter-reporter constructs target expression to specific cell types in human gastric glands. 1.94 kb of uPA promoter, 2.3 kb of uPAR promoter, and 4.5 kb of PAI-1 promoter coupled to a luciferase reporter were transfected into primary human gastric epithelial cells. A: expression of PAI-1-luc (green, left) in a H+/K+ ATPase-positive cell (parietal cell, red, middle; merged image, right). B: expression of PAI-luc (green, left) in a vesicular monoamine transporter (VMAT)-2-positive cell, (ECL cell, red, middle; merged image, right). C: expression of uPA-luc (green, left) in a pepsinogen-positive cell (chief cell, red, middle; merged image, right). D: percentage (%) of PAI-1, uPAR, and uPA luciferase-positive cells expressing H+/K+ATPase, VMAT-2, or pepsinogen (n = 3). Note that <1.0% of uPA- or PAI-1-luc-expressing cells also expressed TFF-1 and that <1.0% of cells expressing all 3 constructs also expressed TFF-2.
###end p 57
###begin p 58
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pylori</italic>
###xml 216 220 216 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagE</italic>
###xml 229 233 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagA</italic>
###xml 238 242 238 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vacA</italic>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pylori</italic>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagE</italic>
###xml 398 402 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagA</italic>
###xml 407 411 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vacA</italic>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 441 442 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 475 484 475 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 498 507 498 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 512 516 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cagE</italic>
###xml 0 9 <span type="species:ncbi:210">H. pylori</span>
###xml 90 99 <span type="species:ncbi:210">H. pylori</span>
###xml 271 280 <span type="species:ncbi:210">H. pylori</span>
###xml 475 484 <span type="species:ncbi:210">H. pylori</span>
###xml 498 507 <span type="species:ncbi:210">H. pylori</span>
H. pylori stimulates uPA, but not uPAR, or PAI-luc through a CagE-dependent mechanism. A: H. pylori [16 h, multiplicity of infection (MOI) 1:150] stimulates expression of uPA-luc that is abolished by deletion of the cagE but not cagA and vacA virulence factors. B and C: H. pylori also stimulates expression of PAI-luc and uPAR-luc, respectively, but this is not decreased by deletion of the cagE, cagA, or vacA virulence factors; n = 3-15, P < 0.05. (*control vs. wild-type H. pylori; **wild-type H. pylori vs. cagE-null mutant). wt, wild-type.
###end p 58
###begin p 59
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 124 125 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 165 174 165 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 289 290 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 319 328 318 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 484 485 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 494 495 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 524 533 521 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 537 546 534 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 557 566 554 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 0 9 <span type="species:ncbi:210">H. pylori</span>
###xml 165 174 <span type="species:ncbi:210">H. pylori</span>
###xml 319 328 <span type="species:ncbi:210">H. pylori</span>
###xml 524 533 <span type="species:ncbi:210">H. pylori</span>
###xml 537 546 <span type="species:ncbi:210">H. pylori</span>
###xml 557 566 <span type="species:ncbi:210">H. pylori</span>
H. pylori increases both cell surface-bound and soluble uPA activity, and PAI-1 knockdown increases activity still further. A: cell surface-bound uPA activity after H. pylori infection with or without PAI-1 antisense oligonucleotide (PAI-1-ASO, 2 muM) treatment expressed as % of control. B: soluble uPA activity after H. pylori infection with or without PAI-1-ASO treatment expressed as % of control. In control cells, the cell surface uPA amounted to 48 +/- 7% of soluble activity; n = 5-13, P < 0.05, ANOVA (*control vs. H. pylori; **H. pylori alone vs. H. pylori with PAI-1 knockdown).
###end p 59
###begin p 60
###xml 63 72 63 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 85 94 85 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 230 231 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 296 305 296 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 376 377 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 426 431 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 453 456 453 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 525 526 525 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 532 533 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 562 571 562 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 582 591 582 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 63 72 <span type="species:ncbi:210">H. pylori</span>
###xml 85 94 <span type="species:ncbi:210">H. pylori</span>
###xml 148 153 <span type="species:ncbi:9606">human</span>
###xml 296 305 <span type="species:ncbi:210">H. pylori</span>
###xml 562 571 <span type="species:ncbi:210">H. pylori</span>
###xml 582 591 <span type="species:ncbi:210">H. pylori</span>
Increased gastric epithelial cell proliferation in response to H. pylori and uPA. A: H. pylori stimulated bromodeoxyuridine (BrdU) incorporation of human primary gastric epithelial cells, and this was enhanced by PAI-1 knockdown. B: addition of uPA (500 ng/ml) mimicked the stimulatory effect of H. pylori on BrdU incorporation, and this was also enhanced by PAI-1 knockdown. C: representative examples of BrdU-labeled cells (right, arrows) in control (top) and uPA-treated glands; DAPI staining of all nuclei shown on left; n = 4, P < 0.05, ANOVA (*control vs. H. pylori or uPA; **H. pylori or uPA along compared with PAI-1). CSO, control scrambled oligonucleotides.
###end p 60
###begin p 61
###xml 63 72 63 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori</italic>
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 96 106 96 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. pylori-</italic>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 363 364 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 63 72 <span type="species:ncbi:210">H. pylori</span>
###xml 96 105 <span type="species:ncbi:210">H. pylori</span>
###xml 139 144 <span type="species:ncbi:9606">human</span>
Increased gastric epithelial cell proliferation in response to H. pylori is mediated by uPA. A: H. pylori-stimulated BrdU incorporation of human primary gastric epithelial cells was inhibited by treatment with neutralizing uPA antibody or knockdown of uPAR with siRNA (60 nM) B: uPA (500 ng/ml)-stimulated BrdU incorporation was also inhibited by uPAR knockdown; n = 3, *P < 0.05, ANOVA. Ab, antibody.
###end p 61
###begin p 62
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 277 278 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 427 428 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 437 438 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
uPA acts through heparin-binding EGF (HB-EGF) to stimulate epithelial cell proliferation. A: uPA (500 ng/ml)-stimulated BrdU incorporation was inhibited by neutralizing Ab to the EGF receptor (EGF-R) (2 mug/ml) and by receptor tyrosine kinase inhibitor (Inh) AG1478 (2 ng/ml). B: uPA-stimulated BrdU incorporation was also inhibited by neutralizing Ab to HB-EGF (5 mug/ml) and by the mutant diphtheria toxin CRM197 (5 mug/ml); n = 3-4, *P < 0.05, ANOVA.
###end p 62

